Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Marco Alessandrini, Sahle Asfaha, Tyren Mark Dodgen, Louise Warnich & Michael Sean Pepper. (2013) Cytochrome P450 pharmacogenetics in African populations. Drug Metabolism Reviews 45:2, pages 253-275.
Read now
Read now
Yukio Horai, Takashi Ishizaki, Michel Eichelbaum, Keitaro Hashimoto, Kan Chiba & Hans J. Dengler. (1988) Further Analysis of Sparteine Oxidation in a Japanese Population and Comparison with Data Observed in Different Ethnic Populations. Xenobiotica 18:9, pages 1077-1084.
Read now
Read now
J. C. Ritchie, M. J. Crothers, R. R. Shah, J. R. Idle & R. L. Smith. (1986) The metabolism of debrisoquine in man: (1) Regioselectivity of hydroxylation and (2) aberrant oxidative metabolism in two sibling patients with carbimazole-induced agranulocytosis. Xenobiotica 16:5, pages 503-509.
Read now
Read now
S. I. Islam, J. R. Idle & R. L. Smith. (1980) The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population. Xenobiotica 10:11, pages 819-825.
Read now
Read now
Articles from other publishers (39)
Iris Rajman, Laura Knapp, Thomas Morgan & Collen Masimirembwa. (2017) African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development. EBioMedicine 17, pages 67-74.
Crossref
Crossref
Howard S. Smith. (2009) Opioid Metabolism. Mayo Clinic Proceedings 84:7, pages 613-624.
Crossref
Crossref
Howard S. Smith. (2009) Opioid Metabolism. Mayo Clinic Proceedings 84:7, pages 613-624.
Crossref
Crossref
Adrián LLerenaPedro DoradoEva M Peñas-Lledó. (2009) Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 10:1, pages 17-28.
Crossref
Crossref
Yueying Zhen, Ondřej Slanař, Kristopher W. Krausz, Chi Chen, Josef Slavík, Kerry L. McPhail, T. Mark Zabriskie, František Perlík, Frank J. Gonzalez & Jeffrey R. Idle. (2006) 3,4-Dehydrodebrisoquine, a Novel Debrisoquine Metabolite Formed from 4-Hydroxydebrisoquine That Affects the CYP2D6 Metabolic Ratio. Drug Metabolism and Disposition 34:9, pages 1563-1574.
Crossref
Crossref
Stephen Bernard, Kathleen A. Neville, Anne T. Nguyen & David A. Flockhart. (2006) Interethnic Differences in Genetic Polymorphisms of CYP2D6 in the U.S. Population: Clinical Implications. The Oncologist 11:2, pages 126-135.
Crossref
Crossref
Takako Shimizu, Hirohide Ochiai, Fredrik Åsell, Hiroshi Shimizu, Ryuta Saitoh, Yoshimasa Hama, Jun Katada, Munehiro Hashimoto, Hitoshi Matsui, Katsuhiko Taki, Tsuguchika Kaminuma, Michiko Yamamoto, Yoshitaka Aida, Akira Ohashi & Naoki Ozawa. (2003) Bioinformatics Research on Inter-racial Difference in Drug Metabolism I. Analysis on Frequencies of Mutant Alleles and Poor Metabolizers on CYP2D6 and CYP2C19. Drug Metabolism and Pharmacokinetics 18:1, pages 48-70.
Crossref
Crossref
Camille P. Granvil, Kristopher W. Krausz, Harry V. Gelboin, Jeffrey R. Idle & Frank J. Gonzalez. (2002) 4-Hydroxylation of Debrisoquine by Human CYP1A1 and Its Inhibition by Quinidine and Quinine. Journal of Pharmacology and Experimental Therapeutics 301:3, pages 1025-1032.
Crossref
Crossref
Poolsup, Li Wan Po & Knight. (2000) Pharmacogenetics and psychopharmacotherapy. Journal of Clinical Pharmacy and Therapeutics 25:3, pages 197-220.
Crossref
Crossref
Lise Bathum, Erik Skjelbo, Theonest K. Mutabingwa, Hanne Madsen, Mogens Hørder & Kim Brøsen. (2001) Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. British Journal of Clinical Pharmacology 48:3, pages 395-401.
Crossref
Crossref
Edyta J Frackiewicz, John J Sramek, John M Herrera, Neil M Kurtz & Neal R Cutler. (2016) Ethnicity and Antipsychotic Response. Annals of Pharmacotherapy 31:11, pages 1360-1369.
Crossref
Crossref
Collen M. Masimirembwa & Julia A. Hasler. (1997) Genetic Polymorphism of Drug Metabolising Enzymes in African Populations: Implications for the Use of Neuroleptics and Antidepressants. Brain Research Bulletin 44:5, pages 561-571.
Crossref
Crossref
Robert J. Straka, Shawn R. Hansen & Patricia F. Walker. (1995) Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota*. Clinical Pharmacology & Therapeutics 58:1, pages 29-34.
Crossref
Crossref
D. Gail May. (2013) Genetic Differences in Drug Disposition. The Journal of Clinical Pharmacology 34:9, pages 881-897.
Crossref
Crossref
E. Spina, G.M. Campo, A. Avenoso, A.P. Caputi, P. Zuccaro, R. Pacifici, G. Gatti, G. Strada, A. Bartoli & E. Perucca. (1994) CYP2D6-related oxidation polymorphism in Italy. Pharmacological Research 29:3, pages 281-289.
Crossref
Crossref
Y. M. Irshaid, H. F. Al-Hadidi & N. M. Rawashdeh. (1993) Dextromethorphan O-demethylation polymorphism in Jordanians. European Journal of Clinical Pharmacology 45:3, pages 271-273.
Crossref
Crossref
A. K. Daly & J. R. Idle. 1993. Cytochrome P450. Cytochrome P450
433
446
.
F. Nsabiyumva, Y. Furet, E. Autret, A. P. Jonville & M. Breteau. (1991) Oxidative polymorphism of dextromethorphan in a Burundi population. European Journal of Clinical Pharmacology 41:1, pages 75-77.
Crossref
Crossref
N.A. Helsby, W.M. Watkins, E. Mberu & S.A. Ward. (1991) Inter-individual variation in the metabolic activation of the antimalarial biguanides. Parasitology Today 7:5, pages 120-123.
Crossref
Crossref
M. S. Lennard. (1990) Genetic Polymorphism of Sparteine/Debrisoquine Oxidation: A Reappraisal. Pharmacology & Toxicology 67:4, pages 273-283.
Crossref
Crossref
G. Boriarti, E. Strocchi, A. Capucci, S. Boschi, B. Marchesini, E. Ambrosioni & B. Magnani. (2012) Relationships Between Debrisoquine Hydroxylation and Propafenone Pharmacokinetics. Drug Investigation 2:2, pages 114-119.
Crossref
Crossref
M. Eichelbaum & A.S. Gross. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects. Pharmacology & Therapeutics 46:3, pages 377-394.
Crossref
Crossref
L. H. Jeyakumar, U. A. Arowoshegbe, O. O. Akinyinka, F. O. Akinbami & E. A. Bababunmi. (1990) Acetylator status of kwashiorkor children in Ibadan (South-West Nigeria). European Journal of Drug Metabolism and Pharmacokinetics 15:1, pages 57-62.
Crossref
Crossref
De K. Sommers, J. Moncrieff & J. Avenant. (2016) Non-correlation between Debrisoquine and Metoprolol Polymorphisms in the Venda. Human Toxicology 8:5, pages 365-368.
Crossref
Crossref
De K. Sommers, J. Moncrieff & J. Avenant. (2016) Metoprolol α-Hydroxylation Polymorphism in the San Bushmen of Southern Africa. Human Toxicology 8:1, pages 39-43.
Crossref
Crossref
M.S. Lennard. (1989) The polymorphic oxidation of beta-adrenoceptor antagonists. Pharmacology & Therapeutics 41:3, pages 461-477.
Crossref
Crossref
De K. Sommers, J. Moncrieff & J. Avenant. (2016) Polymorphism of the 4-Hydroxylation of Debrisoquine in the San Bushmen of Southern Africa. Human Toxicology 7:3, pages 273-276.
Crossref
Crossref
E J Calabrese. (1988) Comparative biology of test species.. Environmental Health Perspectives 77, pages 55-62.
Crossref
Crossref
Edward J. Calabrese. 1988. Carcinogen Risk Assessment. Carcinogen Risk Assessment
115
122
.
Oscar Torres-Alanís, Lourdes Garza-Ocañas & Alfredo Piñeyro-López. 1989. Cell Function and Disease. Cell Function and Disease
189
198
.
I. Roots, G. Heinemeyer, N. Drakoulis & D. Kampf. 1987. Epidemiological Concepts in Clinical Pharmacology. Epidemiological Concepts in Clinical Pharmacology
105
118
.
Edward J. Calabrese. (1986) Animal Extrapolation and the Challenge of Human Heterogeneity. Journal of Pharmaceutical Sciences 75:11, pages 1041-1046.
Crossref
Crossref
J. Vincent, HL Elliott, PA Meredith & JL Reid. (2012) Racial differences in drug responses‐a comparative study of trimazosin and alpha 1‐adrenoceptor responses in normotensive Caucasians and West Africans.. British Journal of Clinical Pharmacology 21:4, pages 401-408.
Crossref
Crossref
M Jurima, T Inaba, D Kadar & W Kalow. (2012) Genetic polymorphism of mephenytoin p(4′)‐hydroxylation: difference between Orientals and Caucasians.. British Journal of Clinical Pharmacology 19:4, pages 483-487.
Crossref
Crossref
D. M. Roden, T. Wang, R. L. Woosley, A. J. J. Wood, R. A. Branch, A. Küpfer & G. R. Wilkinson. 1984. Pharmacokinetics. Pharmacokinetics
217
234
.
Peter J. Meier, Heinz K. Mueller, Bernhard Dick & Urs A. Meyer. (1983) Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology 85:3, pages 682-692.
Crossref
Crossref
D. B. Jack. (1983) Statistical analysis of polymorphic drug metabolism data using the Rosin Rammler Sperling Weibull distribution. European Journal of Clinical Pharmacology 25:4, pages 443-448.
Crossref
Crossref
Adrian Küpfer, Sabah G. Al-Dabbagh, James C. Ritchie, Jeffrey R. Idle & Robert L. Smith. (1982) Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains. Biochemical Pharmacology 31:20, pages 3193-3199.
Crossref
Crossref
MS Lennard, JH Silas, S Freestone & J Trevethick. (2012) Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.. British Journal of Clinical Pharmacology 14:2, pages 301-303.
Crossref
Crossref